Sort by
Refine Your Search
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
Research Career Development Fellowships in the Department of Cell and Developmental Biology, UCL: Expression of Interest for 2025 DEADLINE: The next deadline is 30th January 2026, 5 pm. The Research
-
About us The UCL Institute for Global Health (IGH) is at the heart of UCL’s Grand Challenge of Global Health. The Institute’s vision is for a world where international policy on global health is
-
part of this mission, UCL is launching a five-year, Medical Research Council-funded Deep Network Modelling in Neuro-oncology programme. This pioneering project aims to build a robust framework that
-
. The UCL GOS ICH, together with its clinical partner Great Ormond Street Hospital for Children, forms the largest concentration of children’s health research outside North America. The 2024-29 GOS ICH